Bilastine for the relief of allergy symptoms

Drugs of Today

Volumn 47, Issue 4, 2011, Pages 251-262

  Sádaba Díaz De Rada, Belén ^a   Azanza Perea, J R ^a   Gomez Guiu Hormigos, A ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; BILASTINE; CETIRIZINE; DESLORATADINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYZINE; KETOCONAZOLE; LEVOCETIRIZINE; PLACEBO; UNCLASSIFIED DRUG;

AGE; ALERTNESS; ALLERGIC REACTION; ALLERGIC RHINITIS; COGNITIVE DEFECT; CONTACT DERMATITIS; DRIVING ABILITY; DROWSINESS; DRUG ANTAGONISM; DRUG APPROVAL; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; GLAUCOMA; HEART CONDUCTION; HUMAN; LABORATORY TEST; NONHUMAN; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; URTICARIA;

ADULT; ANIMALS; ANTI-ALLERGIC AGENTS; BENZIMIDAZOLES; DRUG INTERACTIONS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; HYPERSENSITIVITY; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80052734683     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.4.1587029     Document Type: Review

References (43)

1. Bousquet, J., Khaltaev, N., Cruz, A.A. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008, 63(Suppl. 86): 8-160.
2. Bousquet, J., Schunemann, H.J., Zuberbier, T. et al. Development and implementation of guidelines in allergic rhinitis - an ARIA-GA2LEN paper. Allergy 2010, 65(10): 1212-21.
3. Poole, J.A., Rosenwasser, L.J. The role of immunoglobulin E and immune inflammation: implications in allergic rhinitis. Curr Allergy Asthma Rep 2005, 5(3): 252-8.
4. Greaves, M. Chronic urticaria. J Allergy Clin Immunol 2000, 105(4): 664-72.
5. Prenner, B.M. The evolution of pharmacotherapy for rhinitis and urticaria. Allergy Asthma Proc 2001, 22(5): 277-80.
6. Plaut, M., Valentine, M.D. Clinical practice. Allergic rhinitis. N Engl J Med 2005, 353(18): 1934-44.
7. Berger, W.E. Treatment update: allergic rhinitis. Allergy Asthma Proc 2001, 22(4): 191-8.
8. van Cauwenberge, P., Bachert, C., Passalacqua, G. et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000, 55(2): 116-34.
9. Zuberbier, T., Maurer, M. Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm Venereol 2007, 87(3): 196-205.
10. Zuberbier, T., Asero, R., Bindslev-Jensen, C. et al. EAACI/GA(2)LEN/EDF/ WAO guideline: management of urticaria. Allergy 2009, 64(10): 1427-43.
11. Mattila, M.J., Paakkari, I. Variations among non-sedating antihistamines: are there real differences? Eur J Clin Pharmacol 1999, 55(2): 85-93.
12. Salata, J.J., Jurkiewicz, N.K., Wallace, A.A., Stupienski, R.F., 3rd, Guinosso, P.J., Jr., Lynch, J.J., Jr. Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res 1995, 76(1): 110-9.
13. Broadhurst, P., Nathan, A.W. Cardiac arrest in a young woman with the long QT syndrome and concomitant astemizole ingestion. Br Heart J 1993, 70(5): 469-70.
14. Corcostegui, R., Labeaga, L., Innerarity, A., Berisa, A., Orjales, A. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D 2005, 6(6): 371-84.
15. Wolff, S., Brubaker, K., Navratil, T., Fulcher, E., Lankford, J., Boyer, J. Evaluation of muscarinic receptor antagonism by antihistamines. Allergy [26th Congr Eur Acad Allergol Clin Immunol (EAACI) (June 9-13, Gotenburg) 2007] 2007, 62(Suppl. 83): Abst 365.
16. Alvarez-Mon, M., San Antonio, E., Lucero, M.-L., Sanz, E., Ledo, F., De La Hera, A. Bilastine a novel antihistamine that preferentially inhibits histamine and interleukin-4 release from human mast cells and granulocytes. Allergy [28th Congr Eur Acad Allergol Clin Immunol (EAACI) (June 6-10, Warsaw) 2009] 2009, 64(Suppl. 90): Abst 1454.
17. Corcostegui, R., Labeaga, L., Innerarity, A., Berisa, A., Orjales, A. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs R D 2006, 7(4): 219-31.
18. Gonzalo, A., Lucero, M.L., Orjales, A. Preclinical pharmacokinetics of bilastine, a new anti-histamine drug, in rats and dogs. AAPS J [Annu Meet Am Assoc Pharm Sci (AAPS) San Diego) 2007] 2007, 9(Suppl. 2): Abst W4463.
19. Ganza, A., Gonzalo, A., Lucero, M.L., Orjales, A. Toxicokinetics of bilastine in animals: The effects of the dose and route of administration. Toxicol Lett [45th Congr Eur Societies of Toxicol (Eurotox) (Oct 5-8, Rothes) 2008] 2008, 180(Suppl.): Abst R35.
20. Mumford, R., Allan, L., Hoey, R., Patterson, A., Orjales, A., Lucero, M.L., Crean, C.S. The disposition, metabolism and elimination in rats of bilastine, a potent, selective H1 receptor antagonist. Drug Metab Rev [8th Int ISSX Meet (Oct 9-12, Sendai) 2007] 2007, 39(Suppl. I): Abst 282.
21. Morag, N., Lucero, M.L., Orjales, A. In vitro hepatic metabolism of [14C] bilastine. Drug Metab Rev [8th Int ISSX Meet (Oct 9-12, Sendai) 2007] 2007, 39(Suppl. I): Abst 160.
22. Burton, P.S., Crean, C., Kagey, M., Nielsen, J.W. Permeability characteristics of bilastine, a potent and selective H1 receptor antagonist, in Caco-2 cells. AAPS J [Annu Meet Am Assoc Pharm Sci (Nov 11-15, San Diego) 2007] 2007, 9(S2): Abst T3151.
23. Jauregizar, N., de la Fuente, L., Lucero, M.L., Sologuren, A., Leal, N., Rodriguez, M. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet 2009, 48(8): 543-54.
24. Crean, C., Roupe, K., Sologuren, A., Valiente, R. The pharmacokinetics of bilastine after single and 14 days once daily administration. Basic Clin Pharmacol Toxicol [8th Congr Eur Assoc Clin Pharmacol Ther (Aug 29-Sept 1, Amsterdam) 2007] 2007, 101(Suppl. 1): Abst P252.
25. Bilastine summary. Faes Farma Web site, http://www.faes. es/faesfarma.lasso?LANG=en&FA=a0e97f70983a4b24. Accessed April 18, 2011.
26. Sologuren, A., Lucero, M.L., Valiente, R., Charles, H., Mair, S.J. Human mass balancewith [14C]-bilastine following oral administration to healthy volunteers. Basic Clin Pharmacol Toxicol [9th Congr Eur Assoc Clin Pharmacol Ther (July 12-15, Edinburgh) 2009] 2009, 105(Suppl. 1): Abst TP85.
27. Roupe, K., Sologuren, A., Crean, C., Valiente, R. Effect of age and gender on the pharmacokinetics and pharmacodynamics of bilastine. J Clin Pharmacol [36th Annu Meet Am Coll Clin Pharmacol (ACCP) (Sept 9-11, San Francisco) 2009] 2009, 47(9): Abst 70.
28. Sologuren, A., Valiente, R., Crean, C., McLaverty, D. Relationship of dose to inhibition of wheal and flare for 5 doses of bilastine and 10 mg cetirizine. J Clin Pharmacol [36th Annu Meet Am Coll Clin Pharmacol (ACCP) (Sept 9-11, San Francisco) 2009] 2009, 47(9): Abst 69.
29. Rodríguez, M., Lucero, M.L., Orjales, A., Gonzalo, A., Leal, N., Calvo, R. Estimation of bilastine dose in paediatrics. Can J Clin Pharmacol [IX World Conf Clin Pharmacol Ther (July 27-Aug 1, Quebec City) 2008] 2008, 15(3): Abst 554.
30. Pharmacokinetic study of bilastine in children from 2 to < 12 years of age with either allergic rhinoconjunctivitis (AR) or chronic urticaria (CU) (NCT01081574). ClinicalTrials.gov Web site, Accessed April 18, 2011.
31. Arteche, J.K., Ledo, F., Casadesus, A., Canut, L., Gomez, F., Tortajada, A., Lucero, M.L. Bilastine. Preclinical toxicology review. Toxicol Lett [XII Int Congr Toxicol (July 19-23, Barcelona) 2010] 2010, 196(Suppl.): Abst P302-026.
32. Sommer, E., Weber, K., Lucero, M.L., Arteche, J.K., Orjales, A. Oncogenicity risk assessment of bilastine, a novel antihistamine compound. Toxicol Lett [45th Congr Eur Societies of Toxicol (Eurotox) (Oct 5-8, Rothes) 2008] 2008, 180(Suppl.): Abst P20.
33. Zuberbier, T., Oanta, A., Bogacka, E. et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010, 65(4): 516-28.
34. Bachert, C., Kuna, P., Sanquer, F. et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009, 64(1): 158-65.
35. Kuna, P., Bachert, C., Nowacki, Z. et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009, 39(9): 1338-47.
36. Sologuren, A., Valiente, R., Allison, M., Tyl, B. A lack of significant effect of bilastine on ventricular repolarization. A thorough QT/QTc study. Allergy [27th Congr Eur Acad Allergol Clin Immunol (EAACI) (June 7-11, Barcelona) 2008] 2008, 63(Suppl. 88): Abst 189.
37. Garcia-Gea, C., Martinez-Colomer, J., Antonijoan, R.M., Valiente, R., Barbanoj, M.J. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol 2008, 28(6): 675-85.
38. García-Gea, C., Clos, S., Antonijoan, R.M., Gich, I., Valiente, R., Barbanoj, M.J. Crossover, randomised, double-blind, double-dummy, placebo and positive standard-controlled, unicenter clinical trial to assess the possible interaction on CNS effects between bilastine (20 mg and 80 mg) and alcohol (0.8 g/kg) after single simultaneous administration in healthy subjects. Basic Clin Pharmacol Toxicol [20th Congr Span Clin Pharmacol Soc (Oct 29-Nov 2, Tenerife) 2006] 2006, 99(Suppl. I): Abst EC13.
39. Conen, S., Theunissen, E.L., Van Oers, A.C., Valiente, R., Ramaekers, J.G. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J Psychopharmacol 2010, Advance publication.
40. Horak, F., Zieglmayer, P., Zieglmayer, R., Lemell, P. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res 2010, 59(5): 391-8.
41. Bachert, C., Kuna, P., Zuberbier, T. Bilastine in allergic rhinoconjunctivitis and urticaria. Allergy 2010, 65(Suppl. s93): 1-13.
42. Crean, C., Valiente, R., Sologuren, A., McLaverty, D. Effect of grapefruit juice on the pharmacokinetics of bilastine. J Clin Pharmacol [36th Annu Meet Am Coll Clin Pharmacol (ACCP) (Sept 9-11, San Francisco) 2007] 2007, 47(9): Abst 71.
43. Crean, C., Sologuren, A., Valiente, R., McLaverty, D. The drug-drug interaction of ketoconazole on bilastine pharmacokinetics. Basic Clin Pharmacol Toxicol [8th Congr Eur Assoc Clin Pharmacol Ther (Aug 29-Sept 1, Amsterdam) 2007] 2007, 101(Suppl. 1): Abst P253.